Drug intelligence / Profile preview

RadiaGel

Development stage: Unknown
Lead developer: Carrington Laboratory
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

RadiaGel is a topical hydrogel developed by Carrington Laboratories and distributed by Medline Industries, specifically indicated for the management of radiation dermatitis and minor burns. As a non-oily, water-soluble medical moisturizer, it functions as an emollient to soothe, soften, and increase moisture levels in skin affected by radiation therapy. It is utilized for skin conditioning both before and during radiation treatment to help maintain skin integrity and alleviate irritation associated with oncological procedures.

Brand names: RadiaGelRadiaGel Hydrogel
Other names: RadiaGel Hydrogel

Beyond the preview

Go deeper on RadiaGel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RadiaGel.

Explore the full profile